MPM et al. in €64m series-B for iTeos Therapeutics

Previous investors Fund +, Vives, Société Régionale d'Investissement de Wallonie (SRIW) and La Société Fédérale de Participations et d'Investissement (SFPI) reinvested in the biotechnology company.

Switzerland-based HBM Partners, China-headquartered 6 Dimensions Capital and US-based Curative Ventures and MPM Capital will be backing iTeos Therapeutics for the first time.

Proceeds from this financing round will support the advancement of several immuno-oncology programmes within iTeos's pipeline.

This financing will also support the company's expansion into its new US-based offices in Cambridge, Massachusetts.

Company
Founded in 2012 and based in Gosselies, iTeos is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies. iTeos was founded and supported in part by investments from the Ludwig Institute Cancer Research (LICR), the Walloon region of Belgium and the European Fund for Economic and Regional Development (FEDER).

People
iTeos Therapeutics – Michel Detheux (CEO).
MPM Capital – Gadicke (co-founder, managing director).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Belgium
• Venture